Hemostemix Inc (HMTXF: OTCQB) | Hemostemix Up-lists to TradeGateExchange in Germany
Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) has announced:
- The company’s shares have begun trading on the TradeGateExchange.De under the symbol 2VF0 on January 27, 2025.
- This listing enables European, EU, and UK investors to directly invest in Hemostemix.
- CEO Thomas Smeenk highlighted:
- Management and directors have invested over $9.1 Million in Hemostemix since 2020.
- Their product, ACP-01, has shown effectiveness in limb preservation, heart function regeneration, and mental acuity improvement.
- Clinical relevance and safety have been demonstrated in 498 treatments across seven studies with 318 subjects.
- Benefits of trading on TradeGateExchange include:
- Extended trading hours
- Real-time market data
- Cost-effective trading
- Efficient order execution
- Dedicated customer support
- Commitment to sustainability
- User-friendly interface
- Robust security measures
- Educational resources
- Hemostemix is a clinical-stage biotechnology company focused on blood-based stem cell therapeutics, aiming to treat patients with limited options worldwide.
This up-listing represents a significant step for Hemostemix in expanding its investor base and increasing its visibility in European markets.
PressAlchemy helps businesses of all size from startups to established companies to turn their news into headlines. Whether you’re announcing a corporate update, sharing a major project milestone, or launching a new product, press release distribution ensures your story reaches the right audience on top platforms. If you own a business or have a story to share, now’s the time to get noticed.
Expand your reach to 900+ Media Networks, 13.3k Journalists, and a global audience of over a billion users! Get your Press Release or Article featured for your business or story – CLICK HERE.
#Hemostemix #HMTXF #OTCQB #Hemostemix #Uplists #TradeGateExchange #Germany
